Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

May 19 2011

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression-free survival (PFS) at the 47^th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 3-7, 2011.

"We are very pleased that this Phase 3 trial met its primary endpoint and demonstrated that axitinib could prolong median PFS to more than six months in patients with previously treated advanced RCC. It is notable that in the subset of patients previously treated with cytokines, axitinib extended median PFS to greater than a year," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "We hope that axitinib will be approved as an additional therapeutic option for patients with advanced RCC, alongside Pfizer's two medications approved in this disease, Sutent and Torisel."